Transplantation and cellular therapy · 2026
Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rodriguez-Rodriguez Sergio, Chiarello Caden, Desai Nihar, Remberger Mats, Chen Carol, Al-Shaibani Eshrak, Alfaro Moya Tommy, Law Arjun Datt, Pasic Ivan, Viswabandya Auro, Michelis Fotios V, Kim Dennis Dong Hwan, Kumar Rajat, Mattsson Jonas, Novitzky-Basso Igor
Аннотация
BACKGROUND: Iron overload, indicated by elevated ferritin, is a potentially modifiable risk factor in allogeneic hematopoietic cell transplantation (allo-HCT); however, its prognostic value remains uncertain.
OBJECTIVES: We evaluated whether pre-transplant ferritin (pre-TF) levels are associated with allo-HCT outcomes, including overall survival (OS), disease-free survival (DFS), relapse incidence, and GVHD incidence.
STUDY DESIGN: We retrospectively analyzed 682 allo-HCT recipients transplanted between 2019 and 2022, with a median follow-up of 37 months. Pre-TF was measured at a median of 17 days before allo-HCT. A time-dependent receiver operating characteristic analysis for 2-year OS defined the optimal pre-TF cut-off of 2209 µg/L (AUC: 0.53, sensitivity 35%, specificity 75%). Propensity score matching (PSM) was performed at a 2:1 ratio (controls:cases, caliper 0.2), balancing pre-transplant characteristics to yield a matched cohort of 417 patients.
RESULTS: The median pre-TF was 1159 µg/L. After PSM, 278 patients (66.7%, n = 278/417) had low pre-TF (< 2209 µg/L), and 139 (33.3%) had high pre-TF (≥ 2209 µg/L). High pre-TF was associated with a higher relapse incidence (HR: 1.484, 95% CI, 1.019 to 2.160, P = .039) and a lower incidence of moderate or severe chronic graft-versus-host disease (cGvHD) (HR: 0.501, 95% CI, 0.298 to 0.843, P = .009). OS did not differ after PSM, and was primarily influenced by HCT-CI and conditioning intensity. No differences were observed in graft dynamics, immune reconstitution, or infections. An exploratory AML-specific analysis (cut-off of 2885 µg/L) showed similar patterns for DFS and cGvHD.
CONCLUSION: Elevated pre-transplant ferritin identifies allo-HCT patients at a higher relapse risk and lower risk of cGvHD. These results suggest that ferritin may be associated with immunomodulatory effects that attenuate the graft-versus-leukemia effect while reducing graft-versus-host disease, although this requires further investigation. Clinically, ferritin may serve as a simple and accessible risk biomarker, warranting prospective validation with disease-specific thresholds and integration of functional iron measures.
OBJECTIVES: We evaluated whether pre-transplant ferritin (pre-TF) levels are associated with allo-HCT outcomes, including overall survival (OS), disease-free survival (DFS), relapse incidence, and GVHD incidence.
STUDY DESIGN: We retrospectively analyzed 682 allo-HCT recipients transplanted between 2019 and 2022, with a median follow-up of 37 months. Pre-TF was measured at a median of 17 days before allo-HCT. A time-dependent receiver operating characteristic analysis for 2-year OS defined the optimal pre-TF cut-off of 2209 µg/L (AUC: 0.53, sensitivity 35%, specificity 75%). Propensity score matching (PSM) was performed at a 2:1 ratio (controls:cases, caliper 0.2), balancing pre-transplant characteristics to yield a matched cohort of 417 patients.
RESULTS: The median pre-TF was 1159 µg/L. After PSM, 278 patients (66.7%, n = 278/417) had low pre-TF (< 2209 µg/L), and 139 (33.3%) had high pre-TF (≥ 2209 µg/L). High pre-TF was associated with a higher relapse incidence (HR: 1.484, 95% CI, 1.019 to 2.160, P = .039) and a lower incidence of moderate or severe chronic graft-versus-host disease (cGvHD) (HR: 0.501, 95% CI, 0.298 to 0.843, P = .009). OS did not differ after PSM, and was primarily influenced by HCT-CI and conditioning intensity. No differences were observed in graft dynamics, immune reconstitution, or infections. An exploratory AML-specific analysis (cut-off of 2885 µg/L) showed similar patterns for DFS and cGvHD.
CONCLUSION: Elevated pre-transplant ferritin identifies allo-HCT patients at a higher relapse risk and lower risk of cGvHD. These results suggest that ferritin may be associated with immunomodulatory effects that attenuate the graft-versus-leukemia effect while reducing graft-versus-host disease, although this requires further investigation. Clinically, ferritin may serve as a simple and accessible risk biomarker, warranting prospective validation with disease-specific thresholds and integration of functional iron measures.